Jacqueline C Barrientos Selected Research

Therapeutics

1/2023	Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model.
1/2022	Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers.
1/2021	Oral PI3K-δ,γ Inhibitor for the Management of People with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Narrative Review on Duvelisib.
1/2021	No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib.
12/2020	Chemotherapy-free frontline therapy for CLL: is it worth it?
1/2020	Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL Registry.
12/2019	Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
11/2019	Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial.
11/2019	Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia.
1/2019	Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jacqueline C Barrientos Research Topics

Disease

36	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 12/2023 - 03/2014
10	Neoplasms (Cancer) 01/2022 - 08/2013
10	Diarrhea 01/2021 - 07/2014
6	Pneumonia (Pneumonitis) 01/2021 - 01/2015
5	Colitis 01/2021 - 01/2015
5	Hemorrhage 01/2021 - 08/2015
4	Disease Progression 01/2023 - 01/2017
4	Lymphocytosis 01/2023 - 06/2014
4	Infections 01/2021 - 08/2015
4	Neutropenia 01/2021 - 12/2016
4	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2021 - 08/2013
3	Atrial Fibrillation 01/2020 - 12/2018
3	Hypertension (High Blood Pressure) 12/2019 - 12/2018
3	Fatigue 01/2019 - 07/2014
2	Leukemia 01/2023 - 11/2019
2	COVID-19 03/2022 - 01/2021
2	Thrombocytopenia (Thrombopenia) 01/2021 - 01/2017
2	Lymphoma (Lymphomas) 11/2020 - 01/2017
2	Fever (Fevers) 01/2017 - 07/2014
2	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 08/2015 - 08/2013
1	Leukocytosis (Pleocytosis) 01/2021
1	Arthralgia (Joint Pain) 01/2020
1	Weight Loss (Weight Reduction) 12/2018
1	Tumor Lysis Syndrome 12/2018
1	Chronic Disease (Chronic Diseases) 12/2018
1	Febrile Neutropenia 01/2017
1	Sudden Death 01/2017
1	Lymphadenopathy 01/2017
1	Exanthema (Rash) 12/2016
1	Intestinal Perforation 01/2016
1	Frailty 10/2015
1	Residual Neoplasm 10/2015
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 08/2015
1	Hematologic Neoplasms (Hematological Malignancy) 01/2015
1	Cough 07/2014
1	Nausea 07/2014
1	Chromosome Aberrations (Chromosome Abnormalities) 07/2014
1	Lymphoid Leukemia 07/2014

Drug/Important Bio-Agent (IBA)

24	ibrutinibIBA 01/2023 - 08/2013
15	Agammaglobulinaemia Tyrosine KinaseIBA 01/2023 - 08/2013
11	idelalisibIBA 01/2021 - 03/2014
10	Rituximab (Mabthera)FDA Link 11/2019 - 03/2014
6	Bendamustine Hydrochloride FDA Link 11/2019 - 05/2015
3	Phosphotransferases (Kinase)IBA 01/2021 - 10/2015
2	duvelisibIBA 01/2023 - 01/2021
2	acalabrutinibIBA 01/2021 - 01/2016
2	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 11/2019 - 07/2014
2	Transaminases (Aminotransferases)IBA 01/2019 - 12/2016
2	ofatumumab FDA Link 12/2018 - 07/2014
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2016 - 01/2015
1	serum P-component (CIt)IBA 12/2023
1	Chlorambucil (Leukeran)FDA Link 01/2023
1	mRNA VaccinesIBA 03/2022
1	VaccinesIBA 03/2022
1	Messenger RNA (mRNA)IBA 03/2022
1	umbralisibIBA 01/2021
1	Immunosuppressive Agents (Immunosuppressants)IBA 01/2021
1	Biomarkers (Surrogate Marker)IBA 11/2020
1	Alemtuzumab (Campath)FDA Link 03/2016
1	Monoclonal AntibodiesIBA 10/2015
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 05/2015
1	fludarabineIBA 05/2015
1	SteroidsIBA 01/2015
1	Budesonide (Pulmicort)FDA LinkGeneric 01/2015
1	NucleotidesIBA 07/2014
1	Lenalidomide (CC 5013)FDA Link 07/2014

Therapy/Procedure

22	Therapeutics 01/2023 - 07/2014
3	Drug Therapy (Chemotherapy) 11/2019 - 03/2014
2	Drug Tapering 01/2023 - 01/2019
1	Transplantation 12/2016
1	Cell Transplantation 12/2016